PDCD1 and glioblastoma: Notably, the neoadjuvant administration of pembrolizumab for patients with glioblastoma, followed by continued adjuvant therapy post surgery, has demonstrated a significant extension in the overall survival compared to exclusive adjuvant anti-PD-1 treatment [2].